Literature DB >> 26646999

Follicular Thyroid Adenoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.

Gowri L Kanthan1, James Drummond, Geoff Paul Schembri, Michael A Izard, Edward Hsiao.   

Abstract

68Ga-prostate-specific membrane antigen (PSMA) PET/CT imaging is a relatively new imaging technique used to evaluate the extent of disease in prostate carcinoma. Various other neoplasms may also express PSMA and show uptake on PSMA PET/CT scan. We report a case of a 62-year-old man who had a PSMA PET/CT scan for restaging of prostate carcinoma. A PSMA-avid thyroid lesion was identified, and subsequent tissue sampling confirmed the diagnosis of follicular thyroid adenoma. It is important to be aware of this possibility to avoid scan misinterpretation. Tissue biopsy of PSMA-avid thyroid lesions should be considered to exclude a primary thyroid neoplasm.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26646999     DOI: 10.1097/RLU.0000000000001084

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  18 in total

1.  The Utility of [18F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography.

Authors:  Corinne Beinat; Tom Haywood; Yun-Sheng Chen; Chirag B Patel; Israt S Alam; Surya Murty; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

Review 2.  Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.

Authors:  Prasanna Santhanam; Lilja B Solnes; Steven P Rowe
Journal:  Med Oncol       Date:  2017-10-30       Impact factor: 3.064

3.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

4.  A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.

Authors:  Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-04       Impact factor: 9.236

5.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 6.  PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art.

Authors:  Arnoldo Piccardo; Pierpaolo Trimboli; Luca Foppiani; Giorgio Treglia; Giulia Ferrarazzo; Michela Massollo; Gianluca Bottoni; Luca Giovanella
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

Review 7.  The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.

Authors:  Yishen Wang; Joao R Galante; Athar Haroon; Simon Wan; Asim Afaq; Heather Payne; Jamshed Bomanji; Sola Adeleke; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2022-07-04       Impact factor: 16.430

Review 8.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 9.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

Review 10.  (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.

Authors:  Isabel Rauscher; Tobias Maurer; Wolfgang P Fendler; Wieland H Sommer; Markus Schwaiger; Matthias Eiber
Journal:  Cancer Imaging       Date:  2016-06-08       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.